Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 352

1.

Prediction of non-muscle-invasive bladder cancer recurrence by measurement of checkpoint HLAG's receptor ILT2 on peripheral CD8+ T cells.

Desgrandchamps F, LeMaoult J, Goujon A, Riviere A, Rivero-Juarez A, Djouadou M, de Gouvello A, Dumont C, Wu CL, Culine S, Verine J, Rouas-Freiss N, Hennequin C, Masson-Lecomte A, Carosella ED.

Oncotarget. 2018 Sep 4;9(69):33160-33169. doi: 10.18632/oncotarget.26036. eCollection 2018 Sep 4.

PMID:
30237859
2.

Refining the use of neoadjuvant chemotherapy in locally advanced bladder cancer: from conviction to optimization.

Culine S, Allory Y, Pfister C.

Transl Androl Urol. 2018 Aug;7(4):757-759. doi: 10.21037/tau.2018.06.11. No abstract available.

3.

Sunitinib Prior to Planned Nephrectomy in Metastatic Renal Cell Carcinoma: Angiogenesis Biomarkers Predict Clinical Outcome in the Prospective Phase II PREINSUT Trial.

Mauge L, Mejean A, Fournier L, Pereira H, Etienne-Grimaldi MC, Levionnois E, Caty A, Abadie-Lacourtoisie S, Culine S, Le Moulec S, Linassier C, Théodore C, Ravaud A, Albiges L, Grine A, Tartour E, Milano G, Gille AS, Verkarre V, Helley D, Oudard S; PREINSUT study group.

Clin Cancer Res. 2018 Jul 30. doi: 10.1158/1078-0432.CCR-18-1045. [Epub ahead of print]

PMID:
30061359
4.

[Impact of neoadjuvant chemotherapy on the peri-operative morbidity of radical cystectomy for muscle invasive bladder cancer].

Michel C, Vordos D, Dumont C, Basset V, Meyer F, Gaudez F, Meria P, Cortesse A, Mongiat-Artus P, de la Taille A, Culine S, Desgrandchamps F, Masson-Lecomte A.

Prog Urol. 2018 Sep;28(10):495-501. doi: 10.1016/j.purol.2018.06.002. Epub 2018 Jul 8. French.

PMID:
29997033
5.

Refining the use of cabazitaxel in metastatic castrate-resistant prostate cancer.

Culine S.

Eur J Cancer. 2018 Jul;97:30-32. doi: 10.1016/j.ejca.2018.04.002. Epub 2018 May 3. No abstract available.

PMID:
29731227
6.

Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer.

Vaughn DJ, Bellmunt J, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Li H, Perini RF, Bajorin DF, de Wit R.

J Clin Oncol. 2018 Jun 1;36(16):1579-1587. doi: 10.1200/JCO.2017.76.9562. Epub 2018 Mar 28.

PMID:
29590008
7.

Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility.

Moktefi A, Pouessel D, Liu J, Sirab N, Maille P, Soyeux P, Bergman CC, Auriault ML, Vordos D, Taille A, Culine S, Allory Y.

Mod Pathol. 2018 Aug;31(8):1270-1281. doi: 10.1038/s41379-018-0023-9. Epub 2018 Feb 21.

PMID:
29467478
8.

Placental Site Trophoblastic Tumor in Nonseminomatous Mixed Germ Cell Tumors of the Testis: a Case Report and Review of the Literature.

Razafimahefa J, Gosset C, Culine S, Mongiat-Artus P, Verine J.

Clin Genitourin Cancer. 2018 Apr;16(2):e349-e354. doi: 10.1016/j.clgc.2017.12.010. Epub 2017 Dec 27. No abstract available.

PMID:
29395947
9.

Choosing a career in oncology: results of a nationwide cross-sectional study.

Faivre JC, Bibault JE, Bellesoeur A, Salleron J, Wack M, Biau J, Cervellera M, Janoray G, Leroy T, Lescut N, Martin V, Molina S, Pichon B, Teyssier C, Thureau S, Mazeron JJ, Roché H, Culine S.

BMC Med Educ. 2018 Jan 15;18(1):15. doi: 10.1186/s12909-018-1117-2.

10.

Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases.

Loriot Y, Pagliaro L, Fléchon A, Mardiak J, Geoffrois L, Kerbrat P, Chevreau C, Delva R, Rolland F, Theodore C, Roubaud G, Gravis G, Eymard JC, Malhaire JP, Linassier C, Habibian M, Martin AL, Journeau F, Reckova M, Logothetis C, Laplanche A, Le Teuff G, Culine S, Fizazi K.

Eur J Cancer. 2017 Dec;87:140-146. doi: 10.1016/j.ejca.2017.09.029. Epub 2017 Nov 14.

PMID:
29149760
11.

Customizing Daily Management of Castrate-resistant Prostate Cancer: Waiting for the Next Step.

Culine S.

Eur Urol. 2018 Jul;74(1):24-25. doi: 10.1016/j.eururo.2017.10.016. Epub 2017 Nov 6. No abstract available.

PMID:
29122378
12.

Primary adenocarcinoma of the seminal vesicle.

Terrisse S, Comblor ME, Vérine J, Gauthier H, Mongiat-Artus P, Culine S.

Rare Tumors. 2017 Oct 3;9(3):7074. doi: 10.4081/rt.2017.7074. eCollection 2017 Oct 3.

13.

Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.

Lavaud P, Gravis G, Foulon S, Joly F, Oudard S, Priou F, Latorzeff I, Mourey L, Soulié M, Delva R, Krakowski I, Laguerre B, Théodore C, Ferrero JM, Beuzeboc P, Habibian M, Rolland F, Deplanque G, Pouessel D, Zanetta S, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Tubiana-Mathieu N, Machiels JP, Kouri CE, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Culine S, Boher JM, Tergemina-Clain G, Legoupil C, Fizazi K.

Eur Urol. 2018 May;73(5):696-703. doi: 10.1016/j.eururo.2017.09.022. Epub 2017 Oct 23.

PMID:
29074061
14.

Intratumor heterogeneity of immune checkpoints in primary renal cell cancer: Focus on HLA-G/ILT2/ILT4.

Rouas-Freiss N, LeMaoult J, Verine J, Tronik-Le Roux D, Culine S, Hennequin C, Desgrandchamps F, Carosella ED.

Oncoimmunology. 2017 Jul 5;6(9):e1342023. doi: 10.1080/2162402X.2017.1342023. eCollection 2017.

15.

Q-TWiST analysis of patients with metastatic castrate naive prostate cancer treated by androgen deprivation therapy with or without docetaxel in the randomised phase III GETUG-AFU 15 trial.

Marino P, Sfumato P, Joly F, Fizazi K, Oudard S, Culine S, Habibian M, Boher JM, Gravis G.

Eur J Cancer. 2017 Oct;84:27-33. doi: 10.1016/j.ejca.2017.07.008. Epub 2017 Aug 4.

PMID:
28780479
16.

Prognostic value of the G8 and modified-G8 screening tools for multidimensional health problems in older patients with cancer.

Martinez-Tapia C, Paillaud E, Liuu E, Tournigand C, Ibrahim R, Fossey-Diaz V, Culine S, Canoui-Poitrine F, Audureau E; ELCAPA Study Group.

Eur J Cancer. 2017 Sep;83:211-219. doi: 10.1016/j.ejca.2017.06.027. Epub 2017 Jul 24.

PMID:
28750273
17.

Real-life patterns of use, safety and effectiveness of sunitinib in first-line therapy of metastatic renal cell carcinoma: the SANTORIN cohort study.

Noize P, Grelaud A, Bay JO, Chevreau C, Gross-Goupil M, Culine S, Ferrière JM, Moulin F, Robinson P, Balestra A, Lamarque S, Bernard MA, Lassalle R, Rouyer M, Droz-Perroteau C, Moore N, Fourrier-Réglat A, Ravaud A.

Pharmacoepidemiol Drug Saf. 2017 Dec;26(12):1561-1569. doi: 10.1002/pds.4228. Epub 2017 Jun 1.

PMID:
28573786
18.

Les traitements combinés dans les formes à haut risque évolutif du cancer de la prostate (localisé ou non).

Monnier L, Culine S, Cormier L.

Presse Med. 2017 Oct;46(10):940-947. doi: 10.1016/j.lpm.2017.03.007. Epub 2017 May 23. French.

PMID:
28549631
19.

Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study.

Colomba E, Le Teuff G, Eisen T, Stewart GD, Fife K, Larkin J, Biondo A, Pickering L, Srinivasan A, Boyle H, Derosa L, Sternberg CN, Recine F, Ralph C, Saldana C, Barthélémy P, Bernhard JC, Gurney H, Verhoest G, Vauleon E, Bigot P, Berger J, Pfister C, Gravis G, Rodier JM, Culine S, Caty A, Rolland F, Priou F, Escudier B, Albiges L.

Eur J Cancer. 2017 Jul;80:55-62. doi: 10.1016/j.ejca.2017.03.011. Epub 2017 May 23.

PMID:
28549248
20.

Posterior reversible encephalopathy syndrome with colitis in a patient treated with panitumumab.

Blaye C, Buy X, Gross-Goupil M, Vincent D, Jamet C, Sargos P, Culine S, Roubaud G.

Ther Adv Drug Saf. 2017 Apr;8(4):133-136. doi: 10.1177/2042098616682720. Epub 2017 Jan 16. No abstract available.

21.

First-line management of metastatic castrate-resistant prostate cancer patients: Audit of real-life practices.

Turpin A, Pasquier D, Massard C, Berdah JF, Culine S, Penel N.

Bull Cancer. 2017 Jun;104(6):552-558. doi: 10.1016/j.bulcan.2017.02.002. Epub 2017 Apr 5.

PMID:
28390646
22.

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF; KEYNOTE-045 Investigators.

N Engl J Med. 2017 Mar 16;376(11):1015-1026. doi: 10.1056/NEJMoa1613683. Epub 2017 Feb 17.

23.

Evaluation of the Theoretical Teaching of Postgraduate Radiation Oncology Medical Residents in France: a Cross-Sectional Study.

Faivre JC, Bibault JE, Leroy T, Agopiantz M, Salleron J, Wack M, Janoray G, Roché H, Culine S, Rivera S.

J Cancer Educ. 2018 Apr;33(2):383-390. doi: 10.1007/s13187-017-1170-2.

PMID:
28138918
24.

Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Metastatic Urothelial Carcinoma Patients Treated With First-line Chemotherapy: A Large Multicenter Study.

Auvray M, Elaidi R, Ozguroglu M, Guven S, Gauthier H, Culine S, Caty A, Dujardin C, Auclin E, Thibaut C, Combe P, Tartour E, Oudard S.

Clin Genitourin Cancer. 2017 Jun;15(3):e469-e476. doi: 10.1016/j.clgc.2016.10.013. Epub 2016 Nov 16.

PMID:
27964892
25.

Metastatic Renal Cell Carcinoma in a Renal Allograft: A Sustained Complete Remission After Stimulated Rejection.

Champion L, Culine S, Desgranchamps F, Benali K, Verine J, Daugas E.

Am J Transplant. 2017 Apr;17(4):1125-1128. doi: 10.1111/ajt.14151. Epub 2017 Jan 13.

26.

Early chemotherapy discontinuation and mortality in older patients with metastatic bladder cancer: The AGEVIM multicenter cohort study.

Laurent M, Brureau L, Demery ME, Fléchon A, Thuaut AL, Carvahlo-Verlinde M, Bastuji-Garin S, Paillaud E, Canoui-Poitrine F, Culine S.

Urol Oncol. 2017 Jan;35(1):34.e9-34.e16. doi: 10.1016/j.urolonc.2016.08.003. Epub 2016 Oct 6.

PMID:
27720631
27.

To Treat or Not to Treat Metastatic Cancer Patients with Poor Performance Status: a Prospective Experience.

Kullmann T, Gauthier H, Serrate C, Pouessel D, le Maignan C, Misset JL, Culine S.

Pathol Oncol Res. 2017 Jan;23(1):139-144. doi: 10.1007/s12253-016-0111-4. Epub 2016 Sep 7.

PMID:
27605003
28.

A Statistical Approach to Determine the Optimal Duration of Post-Treatment Follow-Up: Application to Metastatic Nonseminomatous Germ Cell Tumors.

Somda SM, Culine S, Chevreau C, Fizazi K, Leconte E, Kramar A, Filleron T.

Clin Genitourin Cancer. 2017 Apr;15(2):230-236. doi: 10.1016/j.clgc.2016.07.023. Epub 2016 Aug 8.

PMID:
27594552
29.

Adjuvant Chemotherapy After Radical Cystectomy for Urothelial Bladder Cancer: Outcome and Prognostic Factors for Survival in a French Multicenter, Contemporary Cohort.

Pouessel D, Bastuji-Garin S, Houédé N, Vordos D, Loriot Y, Chevreau C, Sevin E, Beuzeboc P, Taille A, Le Thuaut A, Allory Y, Culine S.

Clin Genitourin Cancer. 2017 Feb;15(1):e45-e52. doi: 10.1016/j.clgc.2016.07.012. Epub 2016 Jul 21.

PMID:
27554584
30.

Prognostic significance of an early decline in serum alpha-fetoprotein during chemotherapy for ovarian yolk sac tumors.

de la Motte Rouge T, Pautier P, Genestie C, Rey A, Gouy S, Leary A, Haie-Meder C, Kerbrat P, Culine S, Fizazi K, Lhommé C.

Gynecol Oncol. 2016 Sep;142(3):452-7. doi: 10.1016/j.ygyno.2016.07.005. Epub 2016 Jul 8.

PMID:
27401840
31.

Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment.

Pouessel D, Neuzillet Y, Mertens LS, van der Heijden MS, de Jong J, Sanders J, Peters D, Leroy K, Manceau A, Maille P, Soyeux P, Moktefi A, Semprez F, Vordos D, de la Taille A, Hurst CD, Tomlinson DC, Harnden P, Bostrom PJ, Mirtti T, Horenblas S, Loriot Y, Houédé N, Chevreau C, Beuzeboc P, Shariat SF, Sagalowsky AI, Ashfaq R, Burger M, Jewett MA, Zlotta AR, Broeks A, Bapat B, Knowles MA, Lotan Y, van der Kwast TH, Culine S, Allory Y, van Rhijn BW.

Ann Oncol. 2016 Jul;27(7):1311-6. doi: 10.1093/annonc/mdw170. Epub 2016 Apr 18.

32.

[Castration modalities in prostate cancer: Are they all equal?].

Ploussard G, Bruyère F, Culine S, de La Taille A, Hennequin C, Oudard S, Pfister C, Ravery V, Salomon L.

Prog Urol. 2016 Apr;26(5):319-28. doi: 10.1016/j.purol.2016.02.010. Epub 2016 Mar 23. Review. French.

PMID:
27017327
33.

[Effective palliative chemotherapy in a patient with collecting duct carcinoma of a unilateral kidney associated with anuria. Case report].

Kullmann T, Pintér T, Szepesvári Z, Kránitz N, Culine S.

Orv Hetil. 2016 Mar 13;157(11):436-9. doi: 10.1556/650.2016.30387. Hungarian.

PMID:
26947093
34.

Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?

Pouessel D, Chevret S, Rolland F, Gravis G, Geoffrois L, Roubaud G, Terrisse S, Boyle H, Chevreau C, Dauba J, Moriceau G, Alexandre I, Deplanque G, Chapelle A, Vauleon E, Colau A, Audenet F, Grellety T, Culine S.

Eur J Cancer. 2016 Feb;54:69-74. doi: 10.1016/j.ejca.2015.11.017. Epub 2015 Dec 25.

PMID:
26724422
35.

Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1).

De Santis M, Wiechno PJ, Bellmunt J, Lucas C, Su WC, Albiges L, Lin CC, Senkus-Konefka E, Flechon A, Mourey L, Necchi A, Loidl WC, Retz MM, Vaissière N, Culine S.

Ann Oncol. 2016 Mar;27(3):449-54. doi: 10.1093/annonc/mdv609. Epub 2015 Dec 16.

36.

Chronological Age and Risk of Chemotherapy Nonfeasibility: A Real-Life Cohort Study of 153 Stage II or III Colorectal Cancer Patients Given Adjuvant-modified FOLFOX6.

Laurent M, Des Guetz G, Bastuji-Garin S, Culine S, Caillet P, Aparicio T, Audureau E, Carvahlo-Verlinde M, Reinald N, Tournigand C, Landre T, LeThuaut A, Paillaud E, Canouï-Poitrine F.

Am J Clin Oncol. 2018 Jan;41(1):73-80. doi: 10.1097/COC.0000000000000233.

PMID:
26669742
37.

Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial.

Gravis G, Boher JM, Joly F, Soulié M, Albiges L, Priou F, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F, Théodore C, Deplanque G, Ferrero JM, Culine S, Mourey L, Beuzeboc P, Habibian M, Oudard S, Fizazi K; GETUG.

Eur Urol. 2016 Aug;70(2):256-62. doi: 10.1016/j.eururo.2015.11.005. Epub 2015 Nov 21.

PMID:
26610858
38.

Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial.

Blanchard P, Faivre L, Lesaunier F, Salem N, Mesgouez-Nebout N, Deniau-Alexandre E, Rolland F, Ferrero JM, Houédé N, Mourey L, Théodore C, Krakowski I, Berdah JF, Baciuchka M, Laguerre B, Davin JL, Habibian M, Culine S, Laplanche A, Fizazi K.

Int J Radiat Oncol Biol Phys. 2016 Jan 1;94(1):85-92. doi: 10.1016/j.ijrobp.2015.09.020. Epub 2015 Sep 25.

PMID:
26576711
39.

Early objective response may not be a prognostic factor of survival for patients with metastatic urothelial carcinoma: from a retrospective analysis of a cohort of 113 patients.

Roubaud G, Brouste V, Beuzeboc P, Fléchon A, Tosi D, Lavau-Denes S, Chevreau C, Culine S, Oudard S, Quivy A, Pourquier P, Houédé N.

J Negat Results Biomed. 2015 Nov 10;14:18. doi: 10.1186/s12952-015-0037-5.

40.

Facteurs de récidive après curage rétro-péritonéal pour tumeur germinale : étude rétrospective multicentrique.

Murez T, Durand X, Rivoire M, Fournier G, Dariane C, Rouprêt M, Lugagne J, Bosset P, Pignot G, Hetet J, Rigaud J, Safsaf R, Pfister C, Daste A, Sèbe P, Malavaud B, Bossavy J, Houlgatte A, Avances C, Camparo P, Flechon A, Culine S, Iborra F, Mottet N, Coloby P, Soulié M.

Prog Urol. 2014 Nov;24(13):865. doi: 10.1016/j.purol.2014.08.180. Epub 2014 Oct 30. French. No abstract available.

PMID:
26461706
41.

18F-Choline PET/CT and Prostate MRI for Staging Patients With Biochemical Relapse After Irradiation for Prostate Cancer.

Quero L, Vercellino L, de Kerviler E, Mongiat-Artus P, Culine S, Merlet P, Ravery V, Meria P, Desgrandchamps F, Hennequin C.

Clin Nucl Med. 2015 Nov;40(11):e492-5. doi: 10.1097/RLU.0000000000000932.

PMID:
26252326
42.

Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.

Fizazi K, Faivre L, Lesaunier F, Delva R, Gravis G, Rolland F, Priou F, Ferrero JM, Houede N, Mourey L, Theodore C, Krakowski I, Berdah JF, Baciuchka M, Laguerre B, Fléchon A, Ravaud A, Cojean-Zelek I, Oudard S, Labourey JL, Chinet-Charrot P, Legouffe E, Lagrange JL, Linassier C, Deplanque G, Beuzeboc P, Davin JL, Martin AL, Habibian M, Laplanche A, Culine S.

Lancet Oncol. 2015 Jul;16(7):787-94. doi: 10.1016/S1470-2045(15)00011-X. Epub 2015 May 28.

PMID:
26028518
43.

[Molecular biology of castration-resistant prostate cancer].

Doucet L, Terrisse S, Gauthier H, Pouessel D, Le Maignan C, Teixeira L, Culine S.

Bull Cancer. 2015 Jun;102(6):497-500. doi: 10.1016/j.bulcan.2015.04.014. Epub 2015 May 28. Review. French.

PMID:
26028493
44.

[Neoadjuvant chemotherapy in muscular invasive bladder cancer: Complications and consequences with cystectomy].

Benadiba S, Gauthier H, Ploussard G, Mongiat-Artus P, Froger L, Basset V, Pashootan P, Chartier E, Dadoun D, Jacob F, Ravery V, Culine S, Desgrandchamps F.

Prog Urol. 2015 Jul;25(9):549-54. doi: 10.1016/j.purol.2015.04.004. Epub 2015 May 26. French.

PMID:
26022236
45.

First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†.

Ravaud A, Oudard S, De Fromont M, Chevreau C, Gravis G, Zanetta S, Theodore C, Jimenez M, Sevin E, Laguerre B, Rolland F, Ouali M, Culine S, Escudier B.

Ann Oncol. 2015 Jun;26(6):1123-8. doi: 10.1093/annonc/mdv149. Epub 2015 Mar 23.

PMID:
25802238
46.

Editorial Comment to Maintenance monotherapy with gemcitabine after standard platinum-based chemotherapy in patients with advanced urothelial cancer.

Gauthier H, Culine S.

Int J Urol. 2015 May;22(5):495. doi: 10.1111/iju.12745. Epub 2015 Mar 17. No abstract available.

47.

[Management of metastatic bladder cancer].

Gauthier H, Serrate C, Pouessel D, Le Maignan C, Teixeira L, Culine S.

Rev Prat. 2014 Dec;64(10):1405-7. French.

PMID:
25668832
48.

[Neoadjuvant chemotherapy for urothelial tumors].

Culine S.

Rev Prat. 2014 Dec;64(10):1399. French. No abstract available.

PMID:
25665321
49.

[Bladder cancer and urothelial tumors. New therapeutic strategies].

Desgrandchamps F, Hennequin C, Culine S.

Rev Prat. 2014 Dec;64(10):1363-4. French. No abstract available.

PMID:
25665313
50.

Intermediate analysis of a phase II trial assessing gemcitabine and cisplatin in locoregional or metastatic penile squamous cell carcinoma.

Houédé N, Dupuy L, Fléchon A, Beuzeboc P, Gravis G, Laguerre B, Théodore C, Culine S, Filleron T, Chevreau C.

BJU Int. 2016 Mar;117(3):444-9. doi: 10.1111/bju.13054. Epub 2015 Apr 27.

Supplemental Content

Loading ...
Support Center